Total
0
Shares
Claritas Pharmaceuticals (TSX:KLY) forms Nitric Oxide Scientific Advisory Board
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Hemostemix (HEM) has completed its Phase II clinical trial subject follow up, as the final subject completed their last follow-up visit
  • The company is shifting its focus to completing data analyses and reporting associated with finalizing the Phase II clinical trial
  • Hemostemix developed and is commercializing its lead product ACP-01 for treatment of several conditions
  • ACP-01 has been used to treat over 300 patients, and is the subject of a randomized, placebo-controlled, double blind trial
  • Hemostemix is unchanged on the day, with shares of the company trading at C$0.35 at 3:46 pm ET

Hemostemix (HEM) has completed its Phase II clinical trial subject follow-up, as the final subject completed their last follow-up visit.

With subject follow up now finished, the company is shifting its focus to completing the data analyses and reporting associated with finalizing the Phase II clinical trial.

Hemostemix developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.

ACP-01 has been used to treat over 300 patients and is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the company announced the results from its Phase II CLI trial abstract which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to 4.5 years.

Hemostemix is a publicly-traded autologous stem cell therapy company and winner of the World Economic Forum Technology Pioneer Award.

Hemostemix is unchanged on the day, with shares of the company trading at C$0.35 at 3:46 pm ET.

More From The Market Herald
Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

" Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

Assure Holdings (IOM) has been approved to list its shares on the NASDAQ Capital Market.
Levitee Labs - CEO, Pouya Farmand. - The Market Herald Canada

" Levitee Labs (CSE:LVT) announces DTC eligibility

Common shares of Levitee Labs (LVT) are now eligible to be electronically cleared and settled through the DTC.
Avicanna Inc - CEO, Aras Azadian - The Market Herald Canada

" Avicanna (TSX:AVCN) files US patent application for cannabinoid formulation

Avicanna (AVCN) has filed a provisional patent application with the United States Patent and Trademark Office.
Alpha Cognition (TSXV:ACOG) announces $12.5 million public offering

" Alpha Cognition (TSXV:ACOG) announces $12.5 million public offering

Alpha Cognition (ACOG) has announced a C$12.5 million public offering led by Raymond James.